Other languages Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Market Closed - Nasdaq Other stock markets 04:00:03 2024-04-23 pm EDT			5-day change	1st Jan Change
1.36 ^USD	0.00%		-2.86%	+9.68%

01:41pm	Averoa Seeks EU Approval for Chronic Kidney Disease Drug	MT
Apr. 16	Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	Apr. 16
Sector Update: Health Care Stocks Advance Premarket Thursday	Mar. 28
Sector Update: Health Care	Mar. 28
Akebia Therapeutics Shares Jump Pre-Bell on FDA Approval of Anemia Treatment for Chronic Kidney Disease Dialysis Patients	Mar. 28
U.S. FDA approves Akebia's anemia drug	Mar. 27
U.S. FDA approves Akebia's anemia drug	Mar. 27
Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis	Mar. 27
Akebia Therapeutics, Inc. Announces Management Changes, Effective March 22, 2024	Mar. 15
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14
Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	Mar. 14
Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14
Akebia Therapeutics Names Nicholas Grund as Chief Commercial Officer	Jan. 09
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer	Jan. 09
Akebia Therapeutics, Inc. Announces the Appointment of Richard C. Malabre as Chief Accounting Officer and Principal Accounting Officer	Jan. 08
Akebia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Akebia Therapeutics Says FDA Accepts Vadadustat Resubmission	23-10-25
Akebia Therapeutics, Inc. Announces Five Poster Presentations at ASN Kidney Week 2023	23-10-18
Akebia Therapeutics Resubmits New Drug Application to US FDA for Vadadustat	23-09-28
Akebia Therapeutics Says Australia Approves Anemia Oral Drug Vafseo	23-09-26
Akebia Therapeutics, Inc. Revises Revenue Guidance for the Year 2023	23-09-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Other languages

Filters